The influence of major dietary fatty acids on insulin secretion and action

Current Opinion in Lipidology

Volumn 21, Issue 1, 2010, Pages 15-20

  López, Sergio ^a   Bermúdez, Beatriz ^a   Abia, Rocío ^a   Muriana, Francisco J G ^a  

^a INSTITUTO DE LA GRASA   (Spain)

Author keywords

Fatty acids; HDL; Insulin; Oxidized LDL; Postprandial period

Indexed keywords

HIGH DENSITY LIPOPROTEIN; MONOUNSATURATED FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; SATURATED FATTY ACID;

APOPTOSIS; CELL PROTECTION; CELL SURVIVAL; DIABETES MELLITUS; FAT INTAKE; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIETARY FATS; FATTY ACIDS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LIPOPROTEINS, HDL; PHOSPHATIDYLCHOLINES; POSTPRANDIAL PERIOD;

EID: 77649098985     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283346d39     Document Type: Review

References (47)

1. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000; 49:1751-1760.
2. Henquin JC. Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 2009; 52:739-751.
3. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, et al. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes 2006; 55:S16-S23.
4. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5:150-159.
5. Pastromas S, Terzi AB, Tousoulis D, Koulouris S. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol 2008; 126:3-12.
6. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007; 10:142-148.
7. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9:367-377.
8. Miles JM, Nelson RH. Contribution of triglyceride-rich lipoproteins to plasma free fatty acids. Horm Metab Res 2007; 39:726-729.
9. Yu KC, Cooper AD. Postprandial lipoproteins and atherosclerosis. Front Biosci 2001; 6:D332-D354.
10. Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL Curr Opin Lipidol 2008; 19:355-361.
11. Williams KJ. Molecular processes that handle and mishandle dietary lipids. J Clin Invest 2008; 118:3247-3459.
12. MoraS, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118:993-1001.
13. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118:2047-2056.
14. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316.
15. LopezS, Bermudez B, Pacheco YM, et al. Distinctive postprandial modulation of p-cell function and insulin sensitivity by dietary fats, monounsaturated compared with saturated fatty acids. Am J Clin Nutr 2008; 88:638-644.
16. Pappan KL, Pan Z, Kwon G, et al. Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion. J Biol Chem 2005; 280:9023-9029.
17. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51:7-18.
18. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005; 54:1640-1648.
19. Duez H, Lamarche B, Valero R, et al. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008; 117:2369-2376.
20. Pavlic M, Valero R, Duez H, et al. Triglyceride-rich lipoprotein- associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol 2008; 28:1660-1665.
21. Zheng C, Khoo C, Furtado J, et al. Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III. Am J Clin Nutr 2008; 88:272-281.
22. Torres N, Noriega L, Tovar AR. Nutrient modulation of insulin secretion. Vitam Horm 2009; 80:217-244.
23. Vassiliou EK, Gonzalez A, Garcia C, et al. Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems. Lipids Health Dis 2009; 8:25-35.
24. Schnell S, Schaefer M, Schofl C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol 2007; 263:173-180.
25. Alquier T, Peyot ML, Latour MG, et al. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 2009. doi: 10.2337/db09-0362. [Epub ahead of print]
26. Del Guerra S, Bugliani M, D'Aleo V, et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: The role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis 2009. doi: 10.1016/j.numecd.2009.02.008. [Epub ahead of print]
27. Cantley J, Burchfield JG, Pearson GL, et al. Deletion of PKCepsilon selectively enhances the amplifying pathways of glucose-stimulated insulin secretion via increased lipolysis in mouse beta-cells. Diabetes 2009; 58: 1 826-1834.
28. Haber EP, Procopio J, Carvalho CR, et al. New insights into fatty acid modulation of pancreatic beta-cell function. Int Rev Cytol 2006; 248: 1-41.
29. Morgan NG. Fatty acids and beta-cell toxicity. Curr Opin Clin Nutr Metab Care 2009; 12:117-122.
30. Morgan NG, Dhayal S, Diakogiannaki E, Welters HJ. The cytoprotective actions of long-chain mono-unsaturated fatty acids in pancreatic beta-cells. Biochem Soc Trans 2008; 36:905-908.
31. Poitout V, Amyot J, Semache M, et al. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2009. doi:10.1016/j.bbalip.2009.08.006. [Epub ahead of print]
32. Jeffrey KD, Alejandro EU, Luciani DS, et al. Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc Natl Acad Sci USA 2008; 105:8452-8457.
33. Gwiazda KS, Yang TL, Lin Y, Johnson JD. Effects of palmitate on ER and cytosolic Ca2+ homeostasis in beta-cells. Am J Physiol Endocrinol Metab 2009; 296:E690-E701.
34. BacharE, AriavY, Ketzinel-Gilad M, et al. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic beta-cells via activation of mTORC1. PLoS One 2009. doi: 10.1371/journal.pone.0004954.
35. Choi SE, Lee SM, Lee YJ, et al. Protective role of autophagy in palmitate-induced INS-1 beta-cell death. Endocrinology 2009; 150:126-134.
36. Koshkin V, Dai FF, Robson-Doucette CA, et al. Limited mitochondrial per-meabilization is an early manifestation of palmitate-induced lipotoxicity in pancreatic beta-cells. J Biol Chem 2008; 283:7936-7948.
37. Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003; 278:18368-18375.
38. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol 2009; 20:363-369.
39. Tinahones FJ, Murri-Pierri M, Garrido-Sanchez L, et al. Oxidative stress in severely obese persons is greater in those with insulin resistance. Obesity 2009; 17:240-246.
40. Okajima F, Kurihara M, Ono C, et al. Oxidized but not acetylated low-density lipoprotein reduces preproinsulin mRNA expression and secretion of insulin from HIT-T15 cells. Biochim Biophys Acta 2005; 1687:173-180.
41. Abderrahmani A, Niederhauser G, Favre D, et al. Human high-density lipo-protein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabeto-logia 2007; 50:1304-1314.
42. Rye KA, Bursill CA, Lambert G, et al. The metabolism and antiatherogenic properties of HDL. J Lipid Res 2009; 50:S195-S200.
43. Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008; 52:136-144.
44. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009; 119:2103-2111.
45. Nieuwdorp M, Vergeer M, Bisoendial RJ, et al. Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. Dia-betologia 2008; 51:1081-1084.
46. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009; 53:962-971.
47. Olsson AG. Is high HDL cholesterol always good? Ann Med 2009; 41:11-18.